AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2494949 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 4236
Study 2494949 — intervention group
Group type: COMPARATOR
Intervention: Telephone method for random allocation
Number of subjects: 4236
Study 367570 — intervention group
Group type: EXPERIMENTAL
Intervention: BOPP (4-drug regimen)
Number of subjects: 537
Study 367570 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (4-drug regimen)
Number of subjects: 537
Study 367570 — intervention group
Group type: COMPARATOR
Intervention: BOP (3-drug regimen)
Number of subjects: 537
Study 367570 — intervention group
Group type: COMPARATOR
Intervention: OPP (3-drug regimen)
Number of subjects: 537
Study 367570 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy (vinblastine, chlorambucil, or chlorambucil plus monthly vincristine + prednisone)
Number of subjects: 537
Study 367570 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug programs (BOPP and MOPP)
Number of subjects: 537
Study 367570 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who obtained CR
Number of subjects: 537
Study 31594858 — intervention group
Group type: EXPERIMENTAL
Intervention: DMD mutations downstream of DMD exon 45
Number of subjects: 196
Study 31594858 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys of DMD carrier mothers
Number of subjects: 196
Study 28246176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid postconditioning (ILPC) group received an intravenous infusion of 20% intralipid (2 mL/kg) just 10 min before aortic cross‐unclamping
Number of subjects: 73
Study 28246176 — intervention group
Group type: COMPARATOR
Intervention: Control group received an equivalent volume of normal saline
Number of subjects: 73
Study 26084032 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM diet
Number of subjects: 23
Study 26084032 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM + HAMSB diet
Number of subjects: 23
Study 24565127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (10mg)
Number of subjects: 60
Study 24565127 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (10mg)
Number of subjects: 60
Study 22998737 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and decreased fasting insulin
Number of subjects: 339
Study 22998737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 339
Study 19201286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-ounce water swallow challenge
Number of subjects: 56
Study 17966842 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy for 5 weeks
Number of subjects: 10
Study 17966842 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 healthy subjects)
Number of subjects: 10
Study 15363006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital group (Hospital/Home + Hospital/Community)
Number of subjects: 43
Study 15363006 — intervention group
Group type: COMPARATOR
Intervention: Community group (Community/Community)
Number of subjects: 43
Study 11405501 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guided PCI
Number of subjects: 108
Study 11405501 — intervention group
Group type: COMPARATOR
Intervention: CAG guided PCI
Number of subjects: 108
Study 9534083 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO) ingestion during exercise
Number of subjects: 8
Study 9534083 — intervention group
Group type: COMPARATOR
Intervention: Solid carbohydrate (SCE) ingestion with water
Number of subjects: 8
Study 9534083 — intervention group
Group type: COMPARATOR
Intervention: Solid carbohydrate (SCA) ingestion with ad libitum water
Number of subjects: 8
Study 7528485 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d of carbimazole
Number of subjects: 197
Study 7528485 — intervention group
Group type: COMPARATOR
Intervention: Minimal dose required to obtain euthyroidism (low dose)
Number of subjects: 197
Study 7528485 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (60 mg/d)
Number of subjects: 197
Study 2894749 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 2
Study 2894749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31901245 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control (target BG 80-120 mg/dL)
Number of subjects: 100
Study 31901245 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (target BG 180-200 mg/dL)
Number of subjects: 100
Study 29742702 — intervention group
Group type: EXPERIMENTAL
Intervention: Spore Powder of Ganoderma Lucidum (SPGL)
Number of subjects: 42
Study 29742702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28230835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual wean (reduction in pressure by 1 cm every 8 hours until 3 cm H2O)
Number of subjects: 70
Study 28230835 — intervention group
Group type: COMPARATOR
Intervention: Sudden wean (one time NCPAP removal to room air)
Number of subjects: 70
Study 28230835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual wean
Number of subjects: 70
Study 28230835 — intervention group
Group type: COMPARATOR
Intervention: Sudden wean
Number of subjects: 70
Study 25219423 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weekly group intervention plus six monthly maintenance sessions (N=104)
Number of subjects: 200
Study 25219423 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=96)
Number of subjects: 200
Study 23371774 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning with no time pressure
Number of subjects: 0
Study 23371774 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning with time pressure
Number of subjects: 0
Study 23371774 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory
Number of subjects: 0
Study 22025233 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 300
Study 22025233 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 300
Study 18458360 — intervention group
Group type: EXPERIMENTAL
Intervention: Opuntia ficus indica (OFI)
Number of subjects: 10
Study 16532466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal patch
Number of subjects: 659
Study 16532466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 14501397 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 115
Study 14501397 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 115
Study 11186806 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 11
Study 11186806 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-randomized trials
Number of subjects: 11
Study 11186806 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 11
Study 9200250 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with Power Poles
Number of subjects: 32
Study 9200250 — intervention group
Group type: COMPARATOR
Intervention: Walking without Power Poles
Number of subjects: 32
Study 1439447 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate node dissection
Number of subjects: 0
Study 1439447 — intervention group
Group type: COMPARATOR
Intervention: Delayed node dissection
Number of subjects: 0
Study 1439447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approach for axial melanomas
Number of subjects: 0
Study 3095220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine aspirin (150, 300, 600 mg)
Number of subjects: 6
Study 3095220 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin (150, 300, 600 mg)
Number of subjects: 6
Study 3095220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional aspirin (150, 300, 600 mg)
Number of subjects: 6
Study 3095220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29705075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous catheter femoral nerve block (cFNB)
Number of subjects: 85
Study 29705075 — intervention group
Group type: COMPARATOR
Intervention: Single injection femoral nerve block (sFNB)
Number of subjects: 85
Study 29705075 — intervention group
Group type: COMPARATOR
Intervention: sFNB
Number of subjects: 85
Study 27694596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring fixator
Number of subjects: 70
Study 27694596 — intervention group
Group type: COMPARATOR
Intervention: Rail fixator
Number of subjects: 70
Study 24519922 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking training
Number of subjects: 20
Study 24519922 — intervention group
Group type: COMPARATOR
Intervention: Body weight‐supported treadmill training
Number of subjects: 20
Study 22402472 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon extract supplementation (L‐citrulline/L‐arginine, 6 g daily)
Number of subjects: 14
Study 22402472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20304805 — intervention group
Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in V617F-positive cases
Number of subjects: 404
Study 20304805 — intervention group
Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in cases without V617F
Number of subjects: 404
Study 20304805 — intervention group
Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in MPL-positive, V617F-negative cases
Number of subjects: 404
Study 20304805 — intervention group
Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in JAK2 exon 12 mutated cases
Number of subjects: 404
Study 20304805 — intervention group
Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in MPL-mutated cases
Number of subjects: 404
Study 20304805 — intervention group
Group type: COMPARATOR
Intervention: Comparison of JAK2 on 46/1 versus other haplotypes
Number of subjects: 404
Study 18365946 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental support intervention
Number of subjects: 59
Study 18365946 — intervention group
Group type: COMPARATOR
Intervention: Minimum behavioral intervention
Number of subjects: 59
Study 16476804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 60 mg
Number of subjects: 58
Study 16476804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 60 mg and midodrine hydrochloride 5 mg
Number of subjects: 58
Study 16476804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 12962458 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 12962458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10
Study 12962458 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 10
Study 12962458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10988016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20-40 mg daily
Number of subjects: 0
Study 10988016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9187174 — intervention group
Group type: EXPERIMENTAL
Intervention: X Hz group (n=19)
Number of subjects: 68
Study 9187174 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz group (n=19)
Number of subjects: 68
Study 9187174 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic group (n=15)
Number of subjects: 68
Study 9187174 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic group (n=15)
Number of subjects: 68
Study 1645103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0 to 1.0 g/kg) administered alone
Number of subjects: 0
Study 1645103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (4 to 96 mg/70 kg) administered alone
Number of subjects: 0
Study 1645103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine and alcohol administered in combination
Number of subjects: 0
Study 1645103 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study 2409325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX), adriblastine (ADR), and cyclophosphamide (CP) for 12 months in COSS-77.
Number of subjects: 215
Study 2409325 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubled dose of methotrexate (MTX), cisplatinum (CPL) or bleomycin + CP + dactinomycin (BCD) in addition to MTX and ADR for 8 months in COSS-80.
Number of subjects: 215
Study 2409325 — intervention group
Group type: COMPARATOR
Intervention: COSS-80 group (CPL and BCD arms).
Number of subjects: 215
Study 2409325 — intervention group
Group type: COMPARATOR
Intervention: COSS-80 group (with and without fibroblaste-interferon (IF)).
Number of subjects: 215
Study 2409325 — intervention group
Group type: EXPERIMENTAL
Intervention: COSS-80 group (young patients less than 12 years and male patients).
Number of subjects: 215
Study 29498170 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day, N = 47)
Number of subjects: 76
Study 29498170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 29)
Number of subjects: 76
Study 29498170 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day) in T-allele carriers (CT/TT)
Number of subjects: 76
Study 29498170 — intervention group
Group type: COMPARATOR
Intervention: Placebo in CC genotype group
Number of subjects: 76
Study 30446596 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1113
Study 30446596 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1113
Study 30446596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1113
Study 27920083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dosing (BD) of enalapril (20 mg at bedtime)
Number of subjects: 24
Study 27920083 — intervention group
Group type: COMPARATOR
Intervention: Morning dosing (MD) of enalapril (20 mg in the morning)
Number of subjects: 24
Study 24760603 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.1% gel
Number of subjects: 70
Study 24760603 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eyedrops
Number of subjects: 70
Study 24760603 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 70
Study 22790645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 10% fat meal
Number of subjects: 16
Study 22790645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 20% fat meal
Number of subjects: 16
Study 22790645 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) with 30% fat meal (normal-fat meal)
Number of subjects: 16
Study 22790645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 50% fat meal
Number of subjects: 16
Study 22790645 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) fasting
Number of subjects: 16
Study 22790645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with very-low-fat meal (10% fat)
Number of subjects: 16
Study 18799373 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps without needle
Number of subjects: 24
Study 18799373 — intervention group
Group type: COMPARATOR
Intervention: Forceps with needles
Number of subjects: 24
Study 17460336 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+P+A beverage (10 mL/kg body weight)
Number of subjects: 23
Study 17460336 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage (10 mL/kg body weight)
Number of subjects: 23
Study 17460336 — intervention group
Group type: COMPARATOR
Intervention: CHO+P+A vs CHO
Number of subjects: 23
Study 17460336 — intervention group
Group type: COMPARATOR
Intervention: Running performance after CHO and CHO+P+A
Number of subjects: 23
Study 17460336 — intervention group
Group type: COMPARATOR
Intervention: Correlation with treatment differences
Number of subjects: 23
Study 14981007 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation via a gas diffuser
Number of subjects: 20
Study 14981007 — intervention group
Group type: COMPARATOR
Intervention: Control (no CO2 insufflation)
Number of subjects: 20
Study 14981007 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 20
Study 11548917 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (fluid intake restricted)
Number of subjects: 7
Study 11548917 — intervention group
Group type: COMPARATOR
Intervention: EUH (forced to drink to maintain euhydration)
Number of subjects: 7
Study 11548917 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO
Number of subjects: 7
Study 11548917 — intervention group
Group type: COMPARATOR
Intervention: EUH
Number of subjects: 7
Study 9669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose tranexamic acid (20 mg.kg‐1)
Number of subjects: 220
Study 9669014 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose tranexamic acid (50 mg.kg‐1)
Number of subjects: 220
Study 9669014 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose tranexamic acid (100 mg.kg‐1)
Number of subjects: 220
Study 8055263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids (marijuana)
Number of subjects: 57
Study 8055263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11039036 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish applied to teeth
Number of subjects: 33
Study 31103972 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and anti-tuberculosis drug
Number of subjects: 80
Study 31103972 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis drug
Number of subjects: 80
Study 28384390 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Restraint Reduction Program (MRRP) including three educational sessions and two unit-based consultations
Number of subjects: 122
Study 28384390 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 122
Study 25948781 — intervention group
Group type: EXPERIMENTAL
Intervention: High WHtR with inflammation
Number of subjects: 8068
Study 25948781 — intervention group
Group type: EXPERIMENTAL
Intervention: High WHtR without inflammation
Number of subjects: 8068
Study 23265088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 33
Study 21212501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelastic sports tape
Number of subjects: 51
Study 21212501 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Number of subjects: 51
Study 21212501 — intervention group
Group type: COMPARATOR
Intervention: No ankle taping
Number of subjects: 51
Study 19506571 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (500 mg b.i.d. to a maximum of 1500 mg b.i.d.)
Number of subjects: 36
Study 19506571 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 36
Study 16155355 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 28
Study 16155355 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 15202302 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (OPCAB)
Number of subjects: 75
Study 15202302 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass surgery (ONCAB)
Number of subjects: 75
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus LEV (arm B, n = 283)
Number of subjects: 813
Study 11419451 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus LEV (arm A, n = 279)
Number of subjects: 813
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV with IFN-alpha (arm C, n = 251)
Number of subjects: 813
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms combined
Number of subjects: 813
Study 11419451 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus LEV (arm A)
Number of subjects: 813
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus LEV (arm B)
Number of subjects: 813
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV with IFN-alpha (arm C)
Number of subjects: 813
Study 11419451 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 813
Study 9240989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle disk training for 8 weeks
Number of subjects: 20
Study 9240989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 8306514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low work-rate exercise (LWE) for 10 weeks
Number of subjects: 10
Study 8306514 — intervention group
Group type: EXPERIMENTAL
Intervention: High work-rate exercise (HWE) for 10 weeks
Number of subjects: 10
Study 8306514 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LWE and HWE
Number of subjects: 10
Study 3028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (EVI, PAV, CMC)
Number of subjects: 306
Study 3028596 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (CAV)
Number of subjects: 306
Study 31982494 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care plus financial incentives
Number of subjects: 182
Study 31982494 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 182
Study 30902701 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity (≥5 children)
Number of subjects: 35498
Study 30902701 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) <23 kg/m2 with highest parity
Number of subjects: 35498
Study 30902701 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) ≥23 kg/m2 with highest parity
Number of subjects: 35498
Study 30902701 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier age at menarche
Number of subjects: 35498
Study 30902701 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 35498
Study 30902701 — intervention group
Group type: COMPARATOR
Intervention: Age at menopause
Number of subjects: 35498
Study 30902701 — intervention group
Group type: COMPARATOR
Intervention: Use of hormonal therapy
Number of subjects: 35498
Study 27809724 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (Group A)
Number of subjects: 30
Study 27809724 — intervention group
Group type: COMPARATOR
Intervention: Manual subgingival debridement (Group B)
Number of subjects: 30
Study 25947257 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PAL) + Dexamethasone (DEX) on day 1 only
Number of subjects: 82